Prelude Capital Management, LLC Reata Pharmaceuticals Inc Transaction History

Prelude Capital Management, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$79.22 - $105.37 $835,771 - $1.11 Million	10,550 New	10,550 $1.08 Million
Q2 2021 Aug 16, 2021	SELL	$78.27 - $151.29 $786,613 - $1.52 Million	-10,050 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$94.25 - $132.81 $947,212 - $1.33 Million	10,050 New	10,050 $1 Million
Q4 2020 Feb 16, 2021	SELL	$102.03 - $184.62 $780,733 - $1.41 Million	-7,652 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$93.53 - $163.34 $679,682 - $1.19 Million	7,267 Added 1887.53%	7,652 $745,000
Q2 2020 Aug 14, 2020	BUY	$126.3 - $176.56 $48,625 - $67,975	385 New	385 $60,000
Q1 2020 May 15, 2020	SELL	$124.16 - $247.74 $2.41 Million - $4.81 Million	-19,423 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$74.57 - $217.92 $2.57 Million - $7.51 Million	-34,453 Reduced 63.95%	19,423 $3.97 Million
Q3 2019 Nov 14, 2019	BUY	$71.26 - $95.75 $796,829 - $1.07 Million	11,182 Added 26.19%	53,876 $4.33 Million
Q2 2019 Aug 14, 2019	BUY	$77.72 - $94.35 $3.32 Million - $4.03 Million	42,694 New	42,694 $4.03 Million
Q2 2018 Aug 14, 2018	SELL	$19.94 - $40.96 $247,495 - $508,395	-12,412 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$20.0 - $30.19 $248,240 - $374,718	12,412 New	12,412 $255,000

62.7K

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.